India’s drug regulator has prohibited the use of a specific anti-cold drug combination for children under four and mandated appropriate labeling. The decision follows global reports of at least 141 child deaths associated with cough syrups. The regulatory response stems from concerns about the promotion of an unapproved anti-cold formulation for infants, sparking discussions and a subsequent recommendation against its use in that age group.
Also Read: Kerala Records 300 New Covid Cases
Dear Readers,
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
